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Objective. To establish a standardized animal model for liver ﬁbrosis with the same assessment criteria for liver ﬁbrosis studies that
have been established on a uniﬁed platform. Methods. The standardized liver ﬁbrosis model was established using Sprague-Dawley
(SD) rats that either received an intraperitoneal injection of carbon tetrachloride (CCl4)i ns m a l ld o s a g e so ri n g e s t e da ne t h a n o l
solution. Results. The deﬁnite corresponding rules among modeling of diﬀerent weeks and corresponding serology indices as
well as diﬀerent pathological staging can be observed by modeling with small dosages and slow, individualized, and combined
administrations. Conclusion. This method can be used for the standardized establishment of a liver ﬁbrosis model in rats across 5
pathological stages, ranging from S0 to S4, with a high success rate (89.33%) and low death rate (17.3%) because of the application
of multiple hypotoxic chemicals for modeling. We refer to the criteria of Histological Grading and Staging of Chronic Hepatitis
for Fibrosis established by the 10th World Digestive Disease Academic Conference in Los Angeles in September 1994 (revised in
November 2000).
1.Introduction
Currently, there are hundreds of million patients with liver
ﬁbrosis throughout the world, and most cases are caused
by hepatitis viral infections [1–7]. In Asian countries, the
infection rate of hepatitis B has reached 10% of the total
population [8–10], whereas hepatitis C virus (HCV) infec-
tion rates in the western countries remain high. Dr. Hans
Popper, an authority on liver diseases in the USA during the
20th century, has pointed out that “anyone who can stop or
delay liver ﬁbrosis would be able to cure most chronic liver
diseases.” Viral hepatitis, posthepatitic cirrhosis, and hepa-
toma are considered to be the three steps of liver disease.
Most studies on liver diseases throughout the world are
mainly focused on the interruption of pathological progres-
sion to prevent or delay the genesis of hepatic cirrhosis and
hepatoma.
Hepatic cirrhosis is a progressive consequence of liver
ﬁbrosis. Liver ﬁbrosis refers to the accumulation of extra-
cellular matrix (ECM) proteins, which occurs in most types
of chronic diseases. Of these proteins, collagen, which is the
body’s self-repairing protein induced by inﬂammation, most
commonly accumulates. The formation and progression of
liver ﬁbrosis is an extremely complicated, gradual process,
which is mainly reﬂected as sustainable inﬂammation in the
liver inducing an ecological disequilibrium of cells and intra-
cellular substances. Therefore, antiliver ﬁbrosis therapy is a
combined therapy targeting the cause of liver ﬁbrosis and
delaying and interrupting the pathological progression. Only
in this way can we control the progression of chronic hepa-
titis B infection into liver ﬁbrosis and hepatic cirrhosis.
Currently, increasingly more studies are focused on liver
ﬁbrosis using animal models. However, the uniﬁed assess-
ment of these studies’ results is diﬃcult due to multiple2 Gastroenterology Research and Practice
modeling methods and diﬀerent qualities of modeling.
Therefore, it is diﬃcult to generalize some achievements
that seem to have signiﬁcance because of the lack of an
eﬀective assessment of a standardized animal model. The
establishment of a standardized animal model for liver ﬁbro-
sis showed critical signiﬁcance in the study of new clinical
therapies, optimal therapeutic opportunities, assessment of
therapeutic eﬀects, academic communications, and so forth.
Recently, more intensive studies within the pathology
community have been performed on liver ﬁbrosis, and the
deﬁnite diagnostic criteria of liver ﬁbrosis in stages 0–4 have
been deﬁned [11], which provided a signiﬁcant reference for
animal studies of liver ﬁbrosis and a higher respect for the
investigators [12–14]. Undoubtedly, the criteria play critical
roles in the selection of optimal therapeutic opportunities,
assessment of therapies to reverse liver ﬁbrosis, and in basic
research. However, there are few reports on standardizing
the modeling of the diﬀerent pathological stages of liver
ﬁbrosis throughout the world. Therefore, we simulated the
naturalpathologicalprocessofliverﬁbrosisinmaleSprague-
Dawley (SD) rats as accurately as possible using hypotoxic
drugs with combined, low-dose, individualized, and long-
term administration to simulate the pathological changes of
injury. Meanwhile, we found a deﬁnite method to establish
a pathological staging model of liver ﬁbrosis, which pave
a way for the assessment of therapeutic eﬀects in certain
pathological stages.
2.MaterialsandMethods
2.1. Laboratory Animals. A total of 95 male Sprague-Dawley
(SD) rats weighing 280g to 300g were provided by the
Animal Department of Kunming Medical College. The rats
were housed in separate cages under a 12-hour light/dark
cycle with access to food and water ad libitum. The room
temperature was kept around 25◦C, and humidity was 60–
70%. The rats were anesthetized with ether and sacriﬁced for
histopathologic examination following euthanasia.
The welfare of the animals in this study was based on the
regulations of Good Laboratory Practice issued in 1978 by the
US Food and Drug Administration (FDA) and Drug Good
Laboratory Practices (Transitional) issued by the State Food
and Drug Administration (SFDA) in China.
2.1.1. Reagents. The following reagents were used in this
study: 5% ethanol solution, analytical reagent carbon tetra-
chloride (CCl4), edible olive oil, analytical reagent ethyl
ether, and 10% neutral formaldehyde buﬀer (4g KH2PO4
and 6.5g Na2HPO4 dissolved in 900mL distilled water, and
formaldehyde was added to a total volume of 1000mL).
2.1.2.Methods. The10%CCl4 liveroilsolutionwasprepared
with analytical reagent CCl4 and olive oil at a volume ratio of
1:9. The 5% ethanol was prepared with dehydrated ethanol
solution and distilled water at a dilution of 1:20. The rats
were raised for 1 week without adverse reactions. The rats
with normal water, food, and activity were collected in the
study. A total of 95 rats were randomized into 2 groups with
20membersinthecontrolgroupreceivinganintraperitoneal
injection of normal saline and 75 members in the animal
model group using intraperitoneal and subcutaneous injec-
tions of 10% CCl4 liver oil solution at a dose of 1mL/kg
administered twice a week for 15 weeks. The 5% edible
ethanol solution was used as the only drink for experimental
rats. Five rats in the control group were sacriﬁced each week
from the 2nd to the 15th week, and the blood-related indices
were detected for hepatic pathological analysis.
2.1.3. Outcomes. The following general conditions of rats
(including death, activity, appetite, weight, appearance, and
feces) were observed.
2.1.4. Serology Indices. The serum hyaluronic acid (HA),
laminin (LN), precollagen III N-terminal (PIIINP), and
type IV collagen (CIV) levels were detected using radioim-
munoassay. The connective tissue growth factors (CTGFs)
were detected by enzyme-linked immunosorbent assay
(ELISA), according to manufacturer’s instructions.
2.1.5. Hepatic Pathology of Rats. The size, shape, texture, and
color of diseased livers were obtained from live tissue at
the same location, ﬁxed by 10% neutral-balanced formalin
solution, and 4µm serial sections were obtained, followed
by paraﬃn imbedding. Subsequently, HE (Hematoxylin and
Eosin) and VG (Van-Gieson) staining was used to observe
the structural changes of hepatic tissue and hyperplasia
of collagen ﬁbers which can be observed in pathological
sections. The pathological grading was based on the criteria
of Histological Grading and Staging of Chronic Hepatitis
for Fibrosis established by the 10th World Digestive Disease
Academic Conference in Los Angeles in September 1994.
(revised in November 2000) [11, 15]: S0 stage, no ﬁbrosis;
S1 stage, expansion of ﬁbrosis in portal area, localized
perisinusoidal and intralobular ﬁbrosis; S2 stage, peripheral
ﬁbrosis in portal area, formation of ﬁbrous septum, reten-
tion of intralobular architecture; S3 stage, ﬁbrous septum
accompanied by intralobular structural disorders, no hepatic
cirrhosis;S4stage,earlyhepaticcirrhosis.Thelivertissuewas
prepared with conventional sectioning and HE staining, and
ﬁbrosis was observed under light microscopy [16–18].
2.2. Statistical Analysis. All data are expressed as the mean ±
SD. The SPSS 16.0 software (SPSS Inc., Chicago, IL) was
used for statistical analysis. Student’s t-test was used for the
comparison between the means of two samples. ANOVA was
applied for the comparison among the means of multiple
samples.
3. Results
3.1.TheSuccessRateofLiverFibrosisModel. Themodelingof
liverﬁbroseswassuccessfulin67casesin75rats,and13cases
died. The modeling success rate was 89.33%, and the death
rate was 17.3% (consisting of 1 dead case in the 6th week,
2 dead cases in the 8th week, 1 dead case in the 9th week, 1
dead case in the 11th week, 2 dead cases in the 12th week,Gastroenterology Research and Practice 3
Table 1: Results of related indices in diﬀerent stages (mean ± SD).
Stages of hepatic ﬁbrosis n HA LN PIIIP CIV CTGF
S0 10 66.59 ±6.89 107.81 ±12.04 86.75 ±19.26 58.54 ±14.12 0.20 ± 0.13
S1 11 106.29 ±19.49 110.60 ±14.43 105.68 ±20.03 66.95 ±17.06 0.41 ± 0.10
S2 22 164.46 ±37.09 117.24 ±19.86 114.04 ±19.24 90.99 ±27.15 0.59 ± 0.07
S3 11 251.66 ±74.75 139.95 ±25.78 156.96 ±27.18 103.79 ±25.41 0.76 ± 0.09
S4 13 342.54 ±80.72 132.26 ±23.94 170.28 ±17.91 137.83 ±41.56 0.99 ± 0.03
F 54.52 5.431 34.753 15.320 149.680
P 0.000∗ 0.001∗ 0.000∗ 0.000∗ 0.000∗
Notes. ∗denotes P<0.002, and the diﬀerence showed statistical signiﬁcance.
Pairwise comparison. HA: pairwise comparison between S0 and S1 stage showed no signiﬁcant diﬀerence, whereas pair comparisons of other stages showed a
signiﬁcant diﬀerence. LN: pairwise comparison between S0 and S1 stage, S0 and S2 stage, and S3 and S4 stage showed no signiﬁcant diﬀerence, whereas pair
comparisons of other stages showed statistical signiﬁcance. PIIIP: pairwise comparison between S1 and S2 stage and S3 and S4 stage showed no signiﬁcant
diﬀerence, whereas pair comparisons of other stages showed statistical signiﬁcance. CIV: pairwise comparison between S0 and S1 stage and S2 and S3 stage
showed no signiﬁcant diﬀerence, whereas pair comparisons of other stages showed statistical signiﬁcance. CTGF: the comparison between diﬀerent liver
ﬁbrosis stages showed statistical signiﬁcance.
1d e a dc a s ei nt h e1 3 t hw e e k ,1d e a dc a s ei nt h e1 4 t hw e e k ,
1 dead case in the 15th week, and 2 dead cases in the 16th
week). The formation of ﬁbrosis in rats in the modeling
group gradually showed the characteristic manifestations of
the diﬀerent pathological stages from S0 to S4 as the weeks
elapsed. The diﬀuse suppurative inﬂammation was observed
in the abdominal cavity of dead rats during modeling at
autopsy, and necrosis in an extensively large area of liver
tissue accompanied by neutrophil inﬁltration was observed
in liver tissue upon histological observation.
3.2. General Status of Rats. The general status of the rats in
the control group was excellent, and the weight of rats
increased rapidly. The rats in the modeling group showed
weak glossiness of pelage, depressed spirit, depressed appe-
tite, and a total death rate of 10.67%. The weight changes in
the two groups, as a function of modeling time, are shown in
Figure 1.
3.3. Detections of Serology. The levels of serum HA, LN,
PIIINP, CIV, and CTGFs in the modeling group were grad-
ually enhanced from the 1st week. The comparison of these
indices in the modeling groups among diﬀerent weeks and
comparison between the modeling group and control group
in same week showed a signiﬁcant diﬀerence, whereas the
serum HA, LN, PIIINP, and CIV levels in the control group
showed no signiﬁcant diﬀerence in any week (Figure 1). The
serum CTGF levels in the modeling group were signiﬁcantly
higher than in the control group (Table 1).
3.4. Hepatic Pathology in Rats. The liver pathology of rats
in the modeling group were reﬂected by the characteristics
shown in Figures 2–5.
4. Discussion
4.1.TheQualityControloftheEstablishmentofaStandardized
Liver Fibrosis Model. The modeling methods of liver ﬁbrosis
include the induction of a hepatotoxicant, induction of a
high fat diet, immunization, bile duct obstruction, parasite
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Figure 1:Comparisonofweightchangesofratsbetweenthegroups
in each week.
methods, dystrophy methods, and a combined application
of the aforementioned methods [19, 20]. CCl4 was used as
an experimental material for hepatic injury, according to the
principle of chronic hepatic and kidney impairment induced
by low-dosage and multiple administrations of CCl4 since
the 1930s. Until recently, CCl4 was still the most extensively
used hepatic-toxic substance for the induction of liver ﬁbro-
sis in rats [21, 22]. The speciﬁc mechanism might have taken
the following course: CCl4 entered into the animal hepatic
tissue, produced trichloromethyl and trichloromethyl perox-
idebyoxidationintheendoplasmicreticulumofhepaticcells
via a cytochrome P450-dependent mixed-function oxidase.
These free radicals switched on the unsaturated lipid mem-
brane peroxidation, induced serious destruction of the hep-
atic cell membrane and structure of organelles, and caused
hepatic cell injury, degeneration, necrosis, and liver ﬁbrosis
formation induced by a long-term repeated stimulus [23–
25].4 Gastroenterology Research and Practice
Figure 2: The pathological stage of the 2nd–4th week is S1. The
ﬁgure describes the general appearance of liver pathology: the liver
was slightly swollen, the color was slightly gloomy, and the texture
was normal. Under the microscope, the hepatic lobular architecture
was integrated, the structure of chloasma hepaticum was not clear,
the hepatocytes showed vacuolar degeneration, the structure of the
portal area was still clear, and no ﬁbrous hyperplasia was observed.
HE. Bar 5200mm.
Figure 3: The pathological stage of the 5th–8th week is S2. The
ﬁgure was the general appearance of liver pathology: there were evi-
dent swellings of the liver. Under the microscope, the hepatic lobu-
lar architecture was unclear, the arrangement of hepatic plate was
disorganized, the hepatocytes showed vacuolar degeneration, and
the hepatocytes showed necrosis in fragments. The liver sinusoid
was narrowing or disappeared by compression. The ﬁbrosis could
be observed in the portal area but was localized in the lobule. HE.
Bar 5200mm.
The hepatic cellular impairment can be induced 15min
after CCl4 enters the body, which achieved the peak value
at 48h. Subsequently, the liver entered the renovation stage,
and the administration was performed with an interval of 3-
4d. Therefore, readministration during the renovation stage
was performed after hepatic injury was caused by one toxic
infection, the renovation was injured repeatedly, and liver
ﬁbrosis was induced. The animal model of liver ﬁbrosis
induced by CCl4 showed morphologic and pathophysio-
logic aspects similar to human liver ﬁbrosis. Moreover, the
breeding of rats was simple, the modeling in rats was easy,
the time cost was low, and the pathological features were
Figure 4: The pathological stage of the 9th–12th week is S3.
The ﬁgure was the general appearance of liver pathology under
the microscope: the aforementioned conditions of live rats were
aggravated, the peripheral ﬁbrosis in the portal area could be
observed, and the formation of ﬁbrous septum could be observed
locally. HE. Bar 5200mm.
Figure 5: The pathological stage of the 13th–14th week is S4. The
ﬁgure was the general appearance of liver pathology under the
microscope: ﬁbroblasts in the portal area showed evident hyperpla-
sia, the ﬁbrous septum was widened, the grid division was formed
inlivercells,thepseudo-lobuleoftheliverwasformed,andatypical
liver ﬁbrosis was formed, which indicated it was at the stage of
hepatic cirrhosis. HE. Bar 5200mm.
stable and reliable [26, 27]. The animal modeling of liver
ﬁbrosis using CCl4 includes intragastric administration via
the mouth, intraperitoneal injection, and subcutaneous
injection [28–30]. The following were the characteristics of
intraperitoneal and subcutaneous injections. (1) The degree
of liver ﬁbrosis is ideal, and liver ﬁbrosis after hepatitis B
infection could be simulated by the pathological appearance.
(2) The progression of liver ﬁbrosis was directly correlated
with the time elapsed since injection, which is easy to control
for the degree of ﬁbrosis and beneﬁcial for further studies.
(3)Oncetheoperativetechniqueismastered,themodelingis
easy to perform, and the death rate of rats is relatively low.
As it is easy to achieve a relatively low death rate of modeling
withthistechnique,theaforementionedmethodsarebecom-
ing the most commonly administered methods.Gastroenterology Research and Practice 5
In preliminary experiments, we observed that rats
showed signiﬁcant diﬀerences after injection of CCl4 due
to varying animal weights, ages, dosage, and time interval
between two administrations; for instance, small weight,
older age, high dose, and low-time interval between admin-
istrations might induce acute poisoning and death. We con-
sidered the following diﬀerences. (1) The weight of modeling
rats should be 250g–300g, and rats with a lower weight are
more prone to die, whereas the rats with a higher weight are
challenging in standardized modeling because of diﬀerences
in hepatic detoxication. (2) The focus should be placed on
the approach of injection, and suﬃcient experiences should
be accumulated. If the drug solution enters the intestinal
canal, the rats must die of acute stomach (intestinal) toxic
expansion. If the drug solution enters the blood vessels, the
rats must die of acute poisoning. To attenuate the eﬀects of
the struggle of rats during the operation and to avoid biting,
we used plastic bottles with the bottoms removed. The head
and body from the umbilicus of the rat were secured in the
bottle, and one hind leg of the rat was ﬁxed. Subsequently,
the prepared drug solution was injected into the abdominal
cavity of the hypogastric zone; therefore, the rat cannot hurt
the human, and it is easy to ﬁx the position of injection.
(3) The sensations of “breakthrough” and “liberation” from
needle tip needed to be identiﬁed after the injection of the
solution into the abdominal cavity. The administration was
complete when the solution was injected into the abdominal
cavity. (4) The environmental temperature, humidity, noise,
and light should be controlled during the procedures of
animal modeling, and these factors might aﬀect the amount
of ﬂuid intake, which is not beneﬁcial for the standardization
of the animal model.
Based on the liver ﬁbrosis model, multiple mechanisms
are involved in the progression of liver ﬁbrosis pathology.
We tried to control potential factors, including weight, age
(in weeks), and environment, we used CCl4 with ethanol
solution for modeling, and we explored the feasibility and
eﬀectiveness of these models for standardization [12, 31, 32].
Meanwhile, we observed the correlations between serology
indices of liver ﬁbrosis, including HA, LN, PIIINP, CIV,
CTGFs, and pathological staging. We also conﬁrmed the fea-
sibility of the establishment of a standardized animal model
for liver ﬁbrosis [33, 34]. Moreover, we developed a substan-
tial foundation for the establishment of a serology-based,
nontrauma model of liver ﬁbrosis and standardized studies
in the clinical setting.
4.2. Critical Signiﬁcance of Establishment of a Standardized
LiverFibrosisModelinRatsinDiﬀerentPathologicalStages. It
is conﬁrmed that we have found a good deal of ways to treat
liver ﬁbrosis. However, we have no uniﬁed standard to eval-
uate their eﬀectiveness. The establishment of a standardized
animal model in diﬀerent pathological stages might pave
the way for opportunities in the biological therapy of liver
ﬁbrosis and provide a standard for the assessment of thera-
peutic eﬀects.
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